Astrana Q3 10-Q: Record $1.02B Revenue, But Material Weakness Still Unremediated
ASTH has more than doubled off its 52-week low of $18.08.
Summary
Astrana's Q3 10-Q confirms $1.02B revenue and $0.26 diluted EPS, but discloses that the material weakness in internal controls remained unremediated as of September 30, 2026, leaving disclosure controls ineffective.
Key Events · Earnings and Guidance · ASTH
-
Q3 Revenue Tops $1 Billion
Revenue of $1,023.6 million, up 7% from $956.0 million a year earlier, driven by capitation growth as enrollees moved to full risk through the RKKs.
-
Net Income Jumps to $12.95M
Net income attributable to Astrana was $12.952 million, or $0.26 per diluted share, versus $0.373 million ($0.01) in Q3 2025; nine-month net income was $47.1 million.
-
Material Weakness Still Unremediated
Management concluded disclosure controls and procedures were not effective as of September 30, 2026 because the material weakness in accounting for business combinations identified in the prior 10-K had not been remediated.
-
Balance Sheet and Debt Position
Cash and cash equivalents of $396.2 million against total debt of $936.3 million; $258.0 million remained available on the revolver as of September 30, 2026.
Analysis · ASTH · Trade & Services
The growth story flagged in the November 5 earnings release holds up in the 10-Q: revenue of $1,023.6 million (up 7%) and net income attributable to the company of $12.95 million, or $0.26 per diluted share, versus $0.37 million a year earlier. Nine-month figures are stronger still, with revenue up 33% to $2,961.2 million and adjusted EBITDA of $212.4 million. What the filing adds beyond the press release is the control environment. Management states that the material weakness in accounting for business combinations identified in the prior 10-K was still not remediated as of September 30, 2026, and therefore concluded disclosure controls and procedures were not effective. That keeps a governance overhang on the stock and matters for anyone underwriting the reliability of acquisition-heavy growth. The balance sheet is stable, with $396.2 million of cash against $936.3 million of debt, and the company also disclosed putative class actions tied to the September cybersecurity incident with no loss provision recorded.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ASTH was trading at $39.01 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $18.08 to $51.60. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.